Press Enter to search · Esc to close
A new BMJ study using UK primary care data compared GLP-1 users head-to-head with other diabetes drugs — and the suicide-risk signal regulators have been chasing didn't show up.
Three new reviews argue we've been measuring the wrong thing. The real target isn't weight — it's the adipose tissue quietly running your metabolism.
A real-world analysis tied to the dulaglutide shortage put concrete numbers on what happens to blood sugar in the three months after stopping. The picture is sobering — and worth bringing to your doctor.